PSTV’s UnitedHealthcare Agreement Puts CNSide Test in Front of 51 Million Covered Lives
In a significant milestone for Plus Therapeutics (Nasdaq: PSTV), the company’s CNSide Cerebrospinal Fluid (CSF) Assay has secured a national coverage agreement with UnitedHealthcare, America’s largest private health insurer. The deal means over 51 million people now have insurance access to this advanced laboratory-developed test for metastatic CNS cancer.
11,000+ CNSide Tests and Counting: Real-World Uptake Bolsters Confidence
Clinical adoption of CNSide has accelerated, with more than 11,000 tests already conducted across over 120 U.S. cancer centers since 2020. This rapid uptake signals growing trust among oncologists, with CNSide now a practical tool in monitoring and guiding treatment for leptomeningeal metastases—a challenging diagnosis for both doctors and patients.
| Key Metrics | Value |
|---|---|
| U.S. Population Covered (millions) | 51 |
| Number of CNSide Tests Performed | 11,000+ |
| Number of Institutions Using CNSide | 120+ |
| Clinical Sensitivity | 92% |
| Clinical Specificity | 95% |
| Cases Where CNSide Influenced Treatment Decisions | 90% |
Clinical Utility: CNSide Delivers High Sensitivity and Specificity in CNS Cancer Detection
What makes CNSide stand out? Its sensitivity (92%) and specificity (95%) set a new bar for non-invasive CNS cancer diagnostics. For patients with metastatic cancers affecting the central nervous system, this means earlier, more precise interventions and fewer diagnostic uncertainties. Peer-reviewed data from nine studies and results from the FORESEE clinical trial underpin these impressive statistics.
Implications for Patients, Providers, and PSTV’s Pipeline
This coverage decision by UnitedHealthcare not only expands access for patients but also paves the way for broader market penetration. CNSide’s exclusivity and growing use reflect its utility and competitive edge in managing leptomeningeal metastases, a population with high unmet need.
The move could signal potential revenue growth for Plus Therapeutics and validate the company’s development approach for next-generation diagnostics and radiotherapeutics. With healthcare systems focused on both clinical outcomes and economic value, broad payer adoption remains a major inflection point for commercial-stage biotech companies like PSTV.
What’s Next for Plus Therapeutics?
With CNSide’s coverage now stretching nationwide and a robust track record from real-world settings, all eyes will be on Plus Therapeutics’ ability to leverage this momentum for additional partnerships, expanded commercialization, and clinical pipeline progress. Investors and patients alike will want to watch for upcoming updates on market traction, new indications, and ongoing clinical validation.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI